Aarti Pharmalabs Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 9 February 2026, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Aarti Pharmalabs declined 35.18% to Rs 47.96 crore in the quarter ended December 2025 as against Rs 73.99 crore during the previous quarter ended December 2024. Sales declined 19.62% to Rs 432.27 crore in the quarter ended December 2025 as against Rs 537.78 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 February 2026.

Powered by Capital Market - Live News

Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025.

Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year.

Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review.

On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

Powered by Capital Market - Live News